X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
100
PharmaCompass offers a list of Ibrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ibrutinib manufacturer or Ibrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ibrutinib manufacturer or Ibrutinib supplier.
PharmaCompass also assists you with knowing the Ibrutinib API Price utilized in the formulation of products. Ibrutinib API Price is not always fixed or binding as the Ibrutinib Price is obtained through a variety of data sources. The Ibrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ibrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibrutinib, including repackagers and relabelers. The FDA regulates Ibrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ibrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ibrutinib supplier is an individual or a company that provides Ibrutinib active pharmaceutical ingredient (API) or Ibrutinib finished formulations upon request. The Ibrutinib suppliers may include Ibrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Ibrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ibrutinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Ibrutinib active pharmaceutical ingredient (API) in detail. Different forms of Ibrutinib DMFs exist exist since differing nations have different regulations, such as Ibrutinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ibrutinib DMF submitted to regulatory agencies in the US is known as a USDMF. Ibrutinib USDMF includes data on Ibrutinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ibrutinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ibrutinib suppliers with USDMF on PharmaCompass.
A Ibrutinib written confirmation (Ibrutinib WC) is an official document issued by a regulatory agency to a Ibrutinib manufacturer, verifying that the manufacturing facility of a Ibrutinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ibrutinib APIs or Ibrutinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Ibrutinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Ibrutinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ibrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ibrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ibrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ibrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ibrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ibrutinib suppliers with NDC on PharmaCompass.
Ibrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ibrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ibrutinib GMP manufacturer or Ibrutinib GMP API supplier for your needs.
A Ibrutinib CoA (Certificate of Analysis) is a formal document that attests to Ibrutinib's compliance with Ibrutinib specifications and serves as a tool for batch-level quality control.
Ibrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Ibrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ibrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ibrutinib EP), Ibrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ibrutinib USP).
Market Place
